Evidence map›Paper›PMID 40458570›Full record

ArticleAsian journal of urology2025

A novel single-port robotic system in urology: A prospective multicenter single-arm clinical trial evaluating feasibility and efficacy of first 50 cases.

Zheng Wang, Chao Zhang, Taile Jing, Yong Wei, Chengwu Xiao, Yang Wang, Yu Fang, Xiaofeng Wu, Shouyan Tang, Hong Xu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. [Current Applications and Future Prospects of Laparoendoscopic Single-Site Surgery in Urology].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zheng WangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Chao ZhangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Taile JingDepartment of Urology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yong WeiDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chengwu XiaoDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yang WangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yu FangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Xiaofeng WuDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Shouyan TangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Hong XuDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Yi LiuDepartment of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China.
Bo YangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Shuo WangDepartment of Urology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Bin XuDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qingyi ZhuDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Dan XiaDepartment of Urology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Zhenjie WuDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Xiaofeng GaoDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Linhui WangDepartment of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to assess the feasibility and safety of the SHURUI single-port robotic surgical system for a range of major urological surgeries. Methods: In this prospective, multicenter clinical trial, we examined the effectiveness of the SHURUI single-port robotic surgical system in urological interventions. The first 50 patients from four centers in China underwent single-port surgeries including partial nephrectomy, radical prostatectomy, partial adrenalectomy, and pyeloureteroplasty, exclusively by the SHURUI single-port robotic surgical system. The study's primary endpoints focused on the success of surgeries, defined as no deviations from planned procedures, no need for more than one port, and no re-operations within 24 h after surgery. Secondary endpoints encompassed a range of surgical metrics, functional outcomes, and patient demographic data. Clinical assessments were conducted before surgery, before discharge, and 1 month after discharge. Results: The surgical procedures were executed successfully without requiring intraoperative conversions or transfusions. Both estimated blood loss and operation durations were maintained within satisfactory limits. For each type of surgery, the mean console times and estimated blood loss were 179.8 (standard deviation [SD] 39.4) min and 125.6 (SD 126.0) mL for radical prostatectomy, 126.7 (SD 47.8) min and 39.2 (SD 54.4) mL for partial nephrectomy, 112.6 (SD 37.4) min and 20.0 (SD 13.2) mL for partial adrenalectomy, and 148.0 (SD 18.2) min and 18.0 (SD 17.9) mL for pyeloureteroplasty, respectively. Across the cohort, 17 patients experienced a total of 25 adverse events, while 10 postoperative complications, all rated as Clavien-Dindo grade I, were encountered by eight patients. All patients had shown recovery or improvement from these events before the end of this trial. Conclusion: The SHURUI single-port robotic surgical system demonstrated feasibility and safety in the performance of major urological surgeries. These initial findings highlight the system's potential, though further research and longer follow-up are required to assess long-term outcomes.

Indexed as

AdrenalectomyClinical trialLaparoendoscopic single-site surgeryNephrectomyProstatectomyPyeloureteroplastyRobotic surgerySingle-port

Identifiers

PMID40458570
PMCPMC12126927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.